Full Papers
Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study
Y. Yazici1, J.R. Tambiah2, C.J. Swearingen3, J. Britt4, S. Kennedy5, M.S. Fineman6, I. Simsek7, E. Solomon8, T.E. Mcalindon9
- Biosplice Therapeutics, Inc. San Diego, CA, and NYU Grossman School of Medicine, New York, NY, USA. yusuf.yazici@biosplice.com
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- Biosplice Therapeutics, Inc. San Diego, CA, USA.
- UMass Chan Medical School and UMass Memorial Medical Center, Boston, MA, USA.
CER17644
Full Papers
PMID: 39808286 [PubMed]
Received: 05/03/2024
Accepted : 02/12/2024
In Press: 13/01/2025
Abstract
OBJECTIVES:
To determine the efficacy, safety, and tolerability of intraarticular (IA) lorecivivint (LOR) in the treatment of knee osteoarthritis (OA).
METHODS:
Patients with American College of Rheumatology criteria-defined knee OA, Kellgren-Lawrence (KL) grades 2–3, and medial Joint Space Width (JSW) by radiograph between 1.5 and 4 mm in the target knee were enrolled in this phase 3, 56-week, multicentre, double-blind, placebo-controlled study. Patients were randomised (1:1) to receive a single IA injection of 0.07 mg LOR or vehicle placebo (PBO) on Day 1. The primary endpoint was the change from baseline in pain Numeric Rating Scale (NRS) at Week 12. Additional outcomes included the change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function, WOMAC Pain, Patient Global Assessment, medial JSW, and safety.
RESULTS:
513 patients were randomised. Baseline mean medial JSW was 2.61 (±0.7) mm. The mean change from baseline in weekly average of daily Pain NRS at Week 12 was LOR -2.24 (± 0.13) compared with PBO -2.49 (± 0.13); p=0.185, 95% confidence interval (CI) (-0.12, 0.62). No discernable treatment effects of LOR compared with PBO were revealed by the analysis of other endpoints. Neither treatment group showed meaningful medial JSW loss over 52 weeks. Incidences, severity, and relationship to study treatment of AEs were similar between LOR and PBO treatment groups.
CONCLUSIOINS: In this study, LOR was well tolerated although it did not meet the primary endpoint of change from baseline in target knee Pain NRS at Week 12.
